Investor relations
Dicot develops a new potency drug that aims to become the first choice globally for the treatment of erectile dysfunction and premature ejaculation.
In August 2023, Dicot started its clinical phase 1 study of the drug candidate LIB-01 with the primary objective of evaluating the safety profile in humans. The first study participants were dosed in early September, and the final clinical visits were made in April 2024. Further development is intended to be carried out under own auspices up to and including clinical phase 2a and then together with major pharmaceutical companies to introduce LIB-01 to the world market.
Dicot's shares are listed on Spotlight Stock Market and the company has approximately 5,500 shareholders.